Guides

Semaglutide vs Tirzepatide

How the two leading GLP-1s compare on results, cost, and side effects.

What Is Retatrutide?

The triple-receptor agonist posting ~24% weight loss in trials.

What Is CagriSema?

Semaglutide plus an amylin analog hitting two satiety systems.

The GLP-1 Pill

How oral GLP-1s compare to injections, and who they suit.

How to Qualify for Semaglutide

BMI thresholds and what the online intake actually checks.

GLP-1 Cost & Eligibility Cheat Sheet

One page: real monthly costs, who qualifies, and what to ask before you pay.

What Is a Compounding Pharmacy?

How compounding pharmacies work and how they are regulated.

Compounded GLP-1s in 2026

What stays accessible after the 2026 compounding crackdown.

Oral Semaglutide vs Orforglipron

Wegovy pill showed 16.6% weight loss vs 12.4% for Foundayo, but no fasting window required.

What Is Amycretin?

Novo Nordisk's GLP-1/amylin dual agonist posted 24.3% weight loss in Phase 2. Phase 3 AMAZE trials started February 2026.

Retatrutide vs CagriSema

TRIUMPH-1: retatrutide 28.3% weight loss at 80 weeks. REDEFINE 1: CagriSema 22.7% at 68 weeks. No head-to-head trial between them exists yet.

Survodutide vs Retatrutide

Both drugs use a glucagon receptor; retatrutide adds GIP on top. TRIUMPH-1: 28.3% weight loss vs SYNCHRONIZE-1: 16.6%. Neither drug is approved.

What Is CX11?

Corxel's oral GLP-1 pill CX11 posted 11.5% weight loss at 36 weeks in Phase 2, with no fasting window required.

What Is Eloralintide?

Lilly's amylin-only obesity drug skips GLP-1 entirely and posted 9.5-20.1% weight loss in Phase 2, with favorable GI tolerability.

What Is KAI-7535?

Hengrui/Kailera's oral GLP-1 pill posted 10.9-11.1% weight loss in Phase 3, but nausea (70%) and vomiting (up to 68.6%) ran far above rival pills.

What Is Petrelintide?

Zealand and Roche's amylin-only obesity drug posted 10.7% weight loss in Phase 2 with placebo-like tolerability. Roche paid $1.65B upfront for it.

How to Prevent GLP-1 Weight Rebound

STEP 1: semaglutide stoppers regained two-thirds of lost weight in a year. SURMOUNT-4: 82% of tirzepatide stoppers regained at least a quarter. What tapering and dosing change.

What Is CT-388 (Enicepatide)?

Roche's dual GLP-1/GIP drug, formerly CT-388, posted 22.5% placebo-adjusted weight loss in a 469-person Phase 2 trial, with no plateau by week 48.

Where to Get Compounded Tirzepatide

503B mass compounding closed in March 2025. A narrow 503A window remains for documented medical need, and Zepbound now runs $299-449/mo, or $50/mo under Medicare.

Tirzepatide and Alcohol

No formal drug interaction, but a 2025 study found tirzepatide delays how fast alcohol hits you, and it compounds real pancreatitis and hypoglycemia risk.

GLP-1 Microdosing for Weight Maintenance

No FDA dose or trial exists below the approved tiers. A Harvard endocrinologist calls microdosing "not a thing," and a lower approved dose is the better-supported alternative.

What Is TIX100?

A UAB-developed, non-GLP-1 oral drug fully blocked weight regain in mice after semaglutide was stopped. Now in Phase 1b human safety trials for type 1 diabetes, with no human weight data yet.

What Is Mazdutide?

Innovent and Lilly's dual GLP-1/glucagon agonist, approved in China since June 2025, beat semaglutide 10.29% to 6% weight loss head-to-head. Not FDA-approved.

What Is MariTide?

Amgen's monthly GLP-1 agonist/GIP-blocking antibody conjugate hit 20% weight loss in Phase 2. Phase 3 MARITIME reads out in early 2027.

Stopping a GLP-1 Before Pregnancy

Manufacturer guidance is to stop about two months before trying to conceive, but only tirzepatide, not semaglutide, cuts oral contraceptive absorption by 20%.

Survodutide vs Tirzepatide

Survodutide cut liver fat 63% and visceral fat 34% in Phase 3. Tirzepatide hit 20.9% weight loss. How the two dual agonists actually compare.

Retatrutide vs Tirzepatide

TRIUMPH-1: retatrutide 28.3% weight loss at 80 weeks vs tirzepatide 20.9% at 72 weeks. The largest efficacy gap in Phase 3 obesity drug history.